Bioo Scientific Launches BRCA1/2 Amplicon Panel for Detection of Somatic Mutations in FFPE Samples

Austin, TX, June 16, 2016 --(PR.com)-- Bioo Scientific recently launched the NEXTflex™ BRCA1 and BRCA2 Amplicon Panel for FFPE Illumina-Compatible Sequencing, for the detection of clinically relevant somatic mutations in DNA isolated from FFPE samples, to facilitate variant discovery and confirmation. This kit is a cost-effective, optimized solution offering best-in-class performance for on-target percentage and coverage uniformity.

The NEXTflex BRCA1 and BRCA2 Amplicon Panels are complete kits that include all components necessary for rapidly generating ready-to-sequence libraries, including primer pairs, library prep reagents, size selection beads, and indexed barcodes.

This kit, facilitating the detection of somatic mutations in the BRCA1/2 genes from DNA isolated from FFPE samples, is Bioo Scientific’s most recent addition to its line of BRCA amplicon panels. Previous kits in this line allow identification of germline mutations in DNA isolated from fresh or frozen materials for both Illumina and Ion Torrent-based sequencing.

To learn how the NEXTflex BRCA1 and BRCA2 Amplicon Panels can improve Illumina or Ion Torrent-based BRCA analysis, visit www.biooscientific.com/BRCA-panels.

About Bioo Scientific Corporation
Bioo Scientific is an Austin, TX based biotechnology company that provides innovative solutions to the life science industry. Bioo Scientific offers a complete portfolio of products that reduce bias and increase the sensitivity, flexibility, and speed of next-generation sequencing.

Bioo Scientific’s products are used around the world and can be purchased both directly or through its global distribution network with markets in more than 100 countries. For more information about Bioo Scientific’s NGS product line, visit www.BiooScientific.com.